Company Short-Term Debt: 23andMe Inc (ME)

Corporate company logo of 23andMe Holding Co. (ME)

Global data analysis for 23andMe Holding Co. (ME) is hindered by digital sovereignty requirements and cyber-sabotage threats, which increase cloud security expenditures. Strategic decline and waning interest in genetics have stripped 23andMe Holding Co. (ME) of its pricing power, fixing the indicator at 0.00. This price chart, serving as confirmation of the market valuation, complements the profile of the DNA testing pioneer, which has maintained its status as a premium brand with exceptional audience trust.

23andMe (ME) - Short-Term Debt from 07/04/2022 to 04/05/2025

Metric breakdowns and analytics for 23andMe Inc (ME)

- stock price and consensus target price:
Stock Price 23andMe|ME - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value 23andMe Holding Co.|ME - Total Company Value
- shareholders' equity book value data:
Accounting Value per Share 23andMe|ME - Total Stockholders' Equity|Market Value to Book Value Ratio 23andme.com|ME - Company Total Asset Base
- company total debt and liquidity indicators:
Total Debt to Capital 23andMe Holding Co.|ME - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity 23andMe Holding Co.|ME - Company Total Debt Obligations|Debt to Book Capitalization Ratio 23andMe Holding Co.|ME - Company Long-Term Liabilities|Company Short-Term Debts 23andMe|Quick Liquidity 23andme.com
- earnings and valuation multiples indicators:
ME - Company Profit
Fundamental company analysis:ME - 23andMe
Manufactured products of 23andMe Holding Co.

To sustain operational activities involving DNA test sales and partnerships with pharma giants, 23andMe Holding Co. (ME) requires effective working capital management. This metric aggregates all credit obligations with maturities of up to one year, allowing investors to assess liquidity risk and the issuer's solvency through the dynamics of the company's short-term borrowings.

Competitor analysis

Agilent - Company Short-Term Debts|DGX - Company Short-Term Debts|Illumina Corp (ILMN) - Company Short-Term Debt|EXAS (Exact Sciences Inc.) - Company Short-Term Debt|Company Current Liabilities RVTY|Short-Term Debt bio-rad.com BIO|Company Short-Term Debt Anbio (NNNN)|Short-Term Debt Volume Sotera Health Corp|Company Short-Term Debts QDEL (QuidelOrtho Corp)|Short-Term Debt Volume OPKO Health Corp. (OPK)|CDNA - Company Short-Term Debt|Short-Term Debt Volume maravai.com MRVI|Fulgent Genetics (FLGT) - Company Short-Term Debt|Company Current Liabilities Standard BioTools Inc|CTKB (Cytek Bio) - Company Short-Term Debts|Company Short-Term Debts OraSure Corp|Company Short-Term Debt Exagen Inc. (XGN)|mdxhealth.com - Company Short-Term Indebtedness|Company Short-Term Debts LUCD (Lucid Diagnostics)|PRE: Company Short-Term Indebtedness|IMDX - Company Short-Term Debt|Trinity Biotech plc (TRIB) - Company Current Liabilities|PRPH: Company Short-Term Debts|Short-Term Debt ainos.com (AIMD)|Company Current Liabilities CODX|HSCS: Company Short-Term Loans and Borrowings|Company Short-Term Debts BMRA|CDIO (cardiodiagnosticsinc.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Virax Biolabs Group VRAX|bluejaydx.com (BJDX) - Short-Term Debt|AWH - Company Short-Term Debt|AXDX: Company Short-Term Debt|CNTG: Company Short-Term Debts|Company Short-Term Indebtedness ENZ|FRES (Fresh2 Group Ltd) - Company Short-Term Debts|GTG Labs (GENE) - Short-Term Debt Volume|Company Short-Term Debt Psychemedics Corporation (PMD)